The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BLRX Detailed Price Forecast - CNN Money||View BLRX Detailed Summary - Google Finance|
|View BLRX Detailed Summary - Yahoo! Finance||View BLRX Stock Research & Analysis - Zacks.com|
|View BLRX Trends & Analysis - Trade-Ideas||View BLRX Major Holders - Barrons|
|View BLRX Call Transcripts - NASDAQ||View BLRX Breaking News & Analysis - Seeking Alpha|
|View BLRX Annual Report - CompanySpotlight.com||View BLRX OTC Short Report - OTCShortReport.com|
|View BLRX Fundamentals - TradeKing||View BLRX SEC Filings - Bar Chart|
|View Historical Prices for BLRX - The WSJ||View Performance/Total Return for BLRX - Morningstar|
|View the Analyst Estimates for BLRX - MarketWatch||View the Earnings History for BLRX - CNBC|
|View the BLRX Earnings - StockMarketWatch||View BLRX Buy or Sell Recommendations - MacroAxis|
|View the BLRX Bullish Patterns - American Bulls||View BLRX Short Pain Metrics - ShortPainBot.com|
|View BLRX Stock Mentions - StockTwits||View BLRX Stock Mentions - PennyStockTweets|
|View BLRX Stock Mentions - Twitter||View BLRX Investment Forum News - Investor Hub|
|View BLRX Stock Mentions - Yahoo! Message Board||View BLRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for BLRX - SECform4.com||View Insider Transactions for BLRX - Insider Cow|
|View BLRX Major Holdings Summary - CNBC||View Insider Disclosure for BLRX - OTC Markets|
|View Insider Transactions for BLRX - Yahoo! Finance||View Institutional Holdings for BLRX - NASDAQ|
|View BLRX Stock Insight & Charts - FinViz.com||View BLRX Investment Charts - StockCharts.com|
|View BLRX Stock Overview & Charts - BarChart||View BLRX User Generated Charts - Trading View|
TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada). As previously announced, the triple combination arm will investigate the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy.
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
Posted on Thursday December 06, 2018
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central Terminal in New York, N.Y. BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4 in late clinical development for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation.
New Healthcare Trends Have Investors Looking at 4 Stocks
Posted on Tuesday November 20, 2018
Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
Posted on Tuesday November 20, 2018
TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company's novel immunotherapy compound. This designation provides the Company with eligibility to obtain 12 years of market exclusivity upon approval of the product for commercial use by the FDA.